Mounjaro And Zepbound Can Help With Weight Loss In People With Long-Term Obesity

Can Mounjaro and Zepbound help with weight loss in people with long-term obesity, and who is eligible in Europe?Mounjaro and Zepbound explained: tirzepatide, GLP-1/GIP receptor agonist therapy, chronic obesity management, BMI criteria, and prescribing standards.In this episode, we review clinical evidence on tirzepatide for long-term obesity and how doctors assess eligibility under EU medical guidance.You’ll learn:• What tirzepatide is and how dual GLP-1/GIP receptor agonists work• Approved BMI thresholds (≥30, or ≥27 with weight-related conditions)• Evidence from clinical trials on average weight reduction• The role of lifestyle intervention alongside medication• Common side effects: nausea, diarrhoea, constipation• Monitoring requirements: HbA1c, kidney function, gallbladder risk• Situations where treatment requests may be declined pending full metabolic assessmentWe explain how doctors assess BMI, waist circumference, blood pressure, HbA1c, lipid profile, previous weight management attempts, and contraindications during an online consultation in the EU. Pharmacotherapy is considered part of structured obesity management, not a standalone solution.This episode reflects the clinical standards used by Mobi Doctor, where weight management consultations are reviewed by a registered physician in line with EU prescribing guidance.Read the full guide and transcript here:https://www.mobidoctor.eu/blog/mounjaro-and-zepbound-can-help-with-weight-loss-in-people-with-long-term-obesity